PAVmed Inc. Q2 FY26 Results

Summary

PAVmed Inc. announced its business update and financial results for the second quarter ended June 30, 2026. The company highlighted significant progress across its subsidiaries, including Veris Health accelerating commercial engagement and Lucid Diagnostics securing a key coverage policy for its EsoGuard® test. The PortIO device also showed promising results in its first-in-human study. Financially, PAVmed reported a GAAP net loss of $5.5 million and a non-GAAP adjusted net loss of $1.7 million for the quarter, while its cash position improved to $3.8 million.

Key Highlights

1. 1

   Veris Health accelerated its commercial engagement with OSU-The James and progressed its implantable physiological monitor towards an early 2027 FDA 510(k) submission.

2. 2

   Lucid Diagnostics secured its first laboratory benefit manager coverage policy for EsoGuard®, recognizing it as medically necessary for patients meeting established screening criteria.

3. 3

   The PortIO first-in-human results were published in the Journal of Vascular Access, demonstrating 100% device patency and no device-related adverse events.

4. 4

   PAVmed reported a GAAP net loss attributable to common stockholders of approximately $5.5 million, or $(0.87) per common share for Q2 2026.

5. 5

   The non-GAAP adjusted net loss for Q2 2026 was approximately $1.7 million, or $(0.27) per common share.

6. 6

   PAVmed's cash and cash equivalents increased to $3.8 million as of June 30, 2026, from $1.5 million as of December 31, 2025.